FY2029 Earnings Estimate for TVTX Issued By HC Wainwright

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Travere Therapeutics in a report issued on Wednesday, January 15th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of $4.22 for the year. HC Wainwright has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share.

Other research analysts have also recently issued reports about the stock. Scotiabank lifted their target price on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Barclays upped their price objective on Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Wells Fargo & Company raised Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Piper Sandler boosted their price target on Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. Finally, Guggenheim increased their price objective on Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Travere Therapeutics Trading Up 5.9 %

Shares of Travere Therapeutics stock opened at $18.07 on Thursday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. Travere Therapeutics has a 1 year low of $5.12 and a 1 year high of $20.33. The firm’s 50-day moving average is $18.21 and its 200 day moving average is $14.34.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million for the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative return on equity of 537.74% and a negative net margin of 172.75%. The company’s quarterly revenue was up 69.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.17) earnings per share.

Insiders Place Their Bets

In other Travere Therapeutics news, insider Jula Inrig sold 2,066 shares of the company’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the completion of the sale, the insider now directly owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. This represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Sandra Calvin sold 15,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $17.22, for a total transaction of $258,300.00. Following the completion of the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at $945,842.94. The trade was a 21.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 29,596 shares of company stock valued at $527,262. Insiders own 4.06% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of TVTX. Aigen Investment Management LP purchased a new position in Travere Therapeutics during the third quarter valued at $170,000. Oppenheimer & Co. Inc. bought a new position in shares of Travere Therapeutics in the third quarter worth about $673,000. Millennium Management LLC lifted its position in shares of Travere Therapeutics by 33.9% during the 2nd quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock valued at $24,244,000 after buying an additional 747,406 shares in the last quarter. FMR LLC grew its stake in shares of Travere Therapeutics by 27.5% during the 3rd quarter. FMR LLC now owns 147,416 shares of the company’s stock valued at $2,062,000 after acquiring an additional 31,772 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in Travere Therapeutics by 18.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 264,816 shares of the company’s stock worth $2,177,000 after acquiring an additional 41,048 shares in the last quarter.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.